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Cisplatin is a chemotherapy drug effective against several forms of cancer, but can
also cause serious side-effects, including nephrotoxicity and ototoxicity. Curcumin, a
natural plant compound, can increase cisplatin’s anti-cancer activity and counteract
cisplatin’s deleterious effect on the auditory and renal systems. Unfortunately, curcumin
exhibits poor bioavailability, which has promoted interest in the development of synthetic
curcumin analogs (curcuminoids) that are soluble, target cancer, and do not cause side
effects. This study investigated whether the curcuminoid (3E,5E)-3,5-bis[(2-fluorophenyl)
methylene]-4-piperidinone (EF-24) increases the anti-cancer effects of cisplatin against a
human ovarian cancer cell line (A2780) and its cisplatin-resistant counterpart (A2780cis),
while preventing cisplatin-mediated side effects in a human kidney cell line (HEK-293T)
and a mouse auditory hybridoma cell line (HEI-OC1). The effect of cisplatin and EF-24
on cellular viability was measured using the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay. The expression and activity of signal
transduction proteins in several apoptotic pathways was measured using caspase
luminescence assays. Reactive oxygen species (ROS) production was also measured using
flow cytometry. Our data suggest that cisplatin and EF-24 are effective against ovarian
cancer cell lines, but both compounds may also have adverse effects on auditory and renal
cells. This project provides relevant information that may improve our understanding of
viii

how these compounds function in different tissues, facilitating improved cancer treatment
and circumvention of side effects commonly associated with cisplatin treatment.
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1. INTRODUCTION
Cancer, the second leading cause of death globally, is a name given to a group of
diseases caused by uncontrolled cell division (Ferlay et al. 2012; Cheung-Ong et al. 2013).
One of the most ubiquitous modalities for treatment is chemotherapy, or a targeted attack
using one or more drugs. The platinum compound cis-diamminedichloroplatinum(II)
(cisplatin) has remained one of the most frequently employed chemotherapies for decades
because of its ability to induce DNA damage in a wide variety of cancers, which activates
apoptotic pathways and initiates production of oncotoxic reactive oxygen species (ROS;
Cepeda et al. 2007; Marullo et al. 2013).
In mammals, the bi-functional platinum-based compound enters the cell through
copper membrane transporter 1 (CTR1). Once in the cytosol, cisplatin undergoes aquation,
during which the chloride leaving ligands are displaced by water molecules, making the
resultant aquated cisplatin a potent electrophile (Dasari et. al 2014). The electrophilic
capabilities of cisplatin allow it to react with sulfhydryl groups, such as those found in
nucleic acids like adenine and guanine. As a result, cisplatin binds to these purine bases
via 1,2-intrastrand cross links, causing damage to the DNA double helix in the form of a
“kink.” This kinking leads to replication arrest, transcription inhibition, cell-cycle arrest,
and to the recruitment of proteins which signal into apoptotic pathways (Cepeda et al.
2007). Cisplatin causes apoptosis in cancer and non-cancer cells by acting through a series
of protease enzymes including caspases-3/7 and -8, and -9 (Karasawa et al. 2015). The
plasma membrane death receptor caspase (caspase-8) and the mitochondrial dysfunction
caspase (caspase-9) are both procaspases upstream of the executioner caspase-3/7 (Dasari
1

et al. 2014). Additionally, cisplatin can induce reactive oxygen species production from a
variety of sources (Marullo et al. 2013). Increased ROS production, as well as activation
of caspases, is implicated in several harmful side-effects of cisplatin treatment, particularly
nephrotoxicity and ototoxicity (Karasawa et. al 2015; Monroe et. al 2018), that also
contribute to cancer cell death (Marullo et al. 2013; Dasari et. al 2014). Thus, considerable
interest exists in development of novel strategies to maintain anticancer efficacy while
mitigating deleterious side effects.
The phytochemical curcumin can destroy cancer cells by influencing the cell cycle,
microRNA expression, proteasomes, and Wnt/β-catenin, NF-κB, and apoptotic signaling,
among other mechanisms (Sohn et al. 2010; Tuorkey 2014). Cisplatin and curcumin can
act against cancer together by signaling through the same pathways causing suppression of
NF-κB and signal transducer and activator of transcription 3 (STAT3), along with downregulating B-cell lymphoma 2 (Bcl-2; He et al. 2016). However, curcumin can also
potentially increase sensitization to cisplatin by downregulating proteins that the platinum
compound does not affect including P-glycoprotein 1 (Pgp1) and multi-drug resistance
protein 1 (MRP1; Salehi et al. 2014; Chen et al. 2015; Shanmugam et al. 2015). Cisplatininduced nephrotoxicity can also be impeded by curcumin through inhibition of TNF-a and
caspase-3 activation (Topcu-Tarladacalisir et al. 2016). Further, curcumin can counteract
cisplatin-modulated pathways that induce ototoxicity by upregulating heme oxygenase 1
(HO-1) and through ROS scavenging activity. Thus, the distinct signaling characteristics
of cisplatin and curcumin suggest that combining them could produce an additive or
synergistic anticancer effect. However, curcumin exhibits limited bioavailability and
solubility, which restricts its efficacy (Teiten et al. 2014; Fridlender et al. 2015).
2

Development of synthetic curcumin derivatives (curcuminoids) which retain anti-cancer
activity and exhibit improved bioavailability have ensued and are ongoing (Tomren et al.
2007; Hussain et al. 2017). The curcuminoid (3E,5E)-3,5-bis[(2-fluorophenyl) methylene]4-piperidinone (EF-24) exhibits superior solubility and acts against cancer by inducing cell
cycle arrest, increasing ROS production, and reducing cell proliferation (Adams et al.
2005; Skoupa et al. 2017; Monroe et al. 2018).
EF-24 may activate the same mechanisms as curcumin, which could mean that
combining this curcuminoid with cisplatin might promote the platinum compound’s anticancer action and prevent its side effects just like curcumin (Selvendiran et al. 2007;
Thomas et al. 2010). EF-24 can modulate several signal transduction pathways that
promote anti-cancer effects. Specifically, this curcuminoid inhibits nuclear factor kappalight-chain-enhancer of activated B cells (NF-κB) signaling and regulates mitogenactivated protein kinase (MAPK), hypoxia-inducible factor 1-alpha (HIF-1a), and ROS
pathways, all of which are implicated in various cancers (Tan et al. 2010; He et al. 2018).
Curcumin also affects the NF-κB and HIF-1a pathways, although through different
modalities than EF-24 (Tomren et al. 2007; De la Garza et al. 2018). Furthermore,
curcumin can increase sensitization to cisplatin by down-regulating membrane proteins
associated with drug resistance, as well as acting as a nephro- and otoprotectant (Rezaee et
al. 2017). Cisplatin-mediated nephrotoxicity and ototoxicity can be caused by oxidative
stress from reactive oxygen species release paired with a decrease in cellular antioxidant
defense mechanisms involving glutathione and superoxide dismutase.

Curcumin,

however, can counteract these effects through stimulation of nuclear factor-like 2 (Nrf2),
a crucial part of the antioxidant response, reducing ROS, and restoring organic anion
3

transporter (OAT) and organic cation transporter (OCT) activity suppressed during
cisplatin treatment (Rezaee et al. 2017).
Cisplatin activates multiple signal transduction pathways, including calcium,
intrinsic and extrinsic apoptosis, protein kinase C (PKC), MAPK signaling, c-Jun Nterminal kinase (JNK) signaling, p38, p53, protein kinase B (PKB/AKT), and ROS to target
cancer cells (Dasari et al. 2014). Because EF-24 and cisplatin activate some of the same
apoptotic pathway components involved in cancer progression (e.g., MAPK and ROS),
their combination could promote a synergistic effect. Furthermore, cisplatin resistance
correlates with increased glutathione production in various cancers (Cepeda et al. 2007),
and EF-24 has been shown to reduce glutathione levels (Skoupa et al. 2017; Rezaee et al.
2017).
Reduced ROS production in response to both curcumin and EF-24 suggests that
EF-24 may be able to combat cisplatin’s harmful side effects in the same way that curcumin
has been proposed to do if it were more bioavailable. The fact that EF-24 has been shown
to reduce cisplatin-mediated ROS production in zebrafish auditory and vestibular tissue
supports this idea (Monroe et al. 2018). In fact, this reduction in ROS yield is similar to
that caused by curcumin in various auditory and renal tissues (Rezaee et al 2017) and
further suggests that EF-24 might be able to counteract cisplatin-mediated increases in
ROS that typically causes hearing-loss and kidney damage (Sergent et al. 2002; Hannigan
et al. 2003; Cepeda et al. 2007; Pabla et al. 2008; Filipski et al. 2009; Miller et al. 2010;
Benard et al. 2014; Salehi et al. 2014; Chen et al. 2015; Horibe et al. 2015; Karasawa et
al. 2015; Wang et al. 2019; Yang et al. 2015). Thus, combining EF-24 with cisplatin may
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minimize the negative consequences of cisplatin chemotherapy while concomitantly
promoting cancer cell cytotoxicity.
The purpose of this project was to investigate how concurrent exposure to both
cisplatin and EF-24 affected cellular viability, several apoptotic mechanisms, and ROS
production in different cancer and non-cancer cell lines. An MTT (3-(4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) cellular viability assay was performed on four cell
lines: A2780 (human ovarian cancer), A2780cis (human ovarian cancer, cisplatinresistant), HEK-293T (human endothelial kidney) and HEI-OC1 (mouse auditory
hybridoma). Additionally, the effects of cisplatin and EF-24 on apoptotic pathways
employing apoptosis caspases-3, -7, -8, and -9 were evaluated in these cell lines using
luminescence assays. Lastly, flow cytometry was employed to measure ROS production in
each cell line.

5

2. METHODOLOGY
2.1. Cell Culture
Cell lines were obtained from Sigma-Aldrich (St. Louis, MO), American Type
Culture Collection (ATCC; Manassas, VA), and Dr. Federico Kalinec (University of
California Los Angeles). The human ovarian cell lines (A2780 and A2780cis) were
cultured in RPMI-1640 media with 2 mM glutamine, 10% fetal bovine serum (FBS) and
1% penicillin/streptomycin. A2780cis resistance was maintained by adding 1 µM cisplatin
to the media every 2-3 passages. The human endothelial kidney cell line (HEK293) was
grown in Eagle’s Minimum Essential Medium (EMEM) with 10% FBS and 1%
penicillin/streptomycin. The mouse auditory hybridoma cell line (HEI-OC1) was cultured
in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS with Amphotericin
B supplementation as required. All cell lines were incubated at 37°C in 5% CO2 with
passaging every 4-7 days, excluding HEI-OC1, which was incubated at 33°C in 10% CO2.
Cell culture media and supplements were obtained from ATCC, Atlanta Biologicals
(Flowery Branch, GA), Mediatech (Tewksbury, MA), Fisher Scientific (Waltham, MA),
Gibco (Gaithersburg, MD) and Sigma-Aldrich.

2.2. Cellular viability assay
MTT cellular viability assays were performed in all four cell lines using a protocol
adapted from Park et al. (2012). Cells were seeded at 5,000 cells per well in 96-well plates
and incubated at 37°C in 5% CO2. Then, wells were treated in replicates of six according
to a concentration series (500, 50, 5, 0.5, 0.05 µM) of cisplatin or EF-24 for 48 hours
(cisplatin) or 24 hours (EF-24). A negative control (media only), positive control (Triton
6

X-100) and series of blanks were simultaneously performed in replicates of six. Each MTT
assay was conducted for two hours, followed by rapid evacuation of all wells, and treatment
with MTT solubilization solution [10% Triton X-100 in acidic (0.1 N HCl) isopropanol]
for 15 minutes before the plates were read using a BioTek Synergy HT (Winooski, VT)
plate reader (570 nm and 690 nm absorbance wavelengths). Once IC50 values were
obtained from these experiments, a subsequent MTT assay was executed in each cell line
as described above, except that the IC50 value for cisplatin was applied to all experimental
wells for 24 hours, followed by application of the EF-24 IC50 value for an additional 24
hours. Following this, the MTT assay was performed according to the protocol described
above. Reagents, cell culture media and supplements were obtained from ATCC, Atlanta
Biologicals, Mediatech, Fisher Scientific, Gibco and Sigma-Aldrich.

2.3. Caspase luminescence assays
This project employed luminescence assays to identify the apoptotic pathways
affected by cisplatin and EF-24 treatment. Caspase activity for caspases-3, -7, -8 and -9
was measured using luciferase assay kits (Promega, Fitchburg, WI). For each luminescent
assay, 10,000 cells were plated in replicates of six in white 96-well plates (Fisher
Scientific) and then placed in an incubator for 24 hours at 37°C in 5% CO2. Cell replicates
were treated for 48 hours with one of the following: the cisplatin IC50, EF-24 IC50, cisplatin
IC50 for 24 hours followed by the EF-24 IC50 for 24 hours, negative control (media with
cells), or blank (media with no cells). Luminogenic substrate was introduced into all wells
for 3 hours, and the plates were read in a plate reader (BioTek).

7

2.4. ROS assay
Cellular ROS production was measured using flow cytometry analysis. For each
cell line, 5-10 cm dishes were seeded with 1.0 x 106 cells in appropriate media for 24 hours
and incubated at 37°C in 5% CO2. After 24 hours, media was aspirated out of each dish.
Subsequent treatments included one of the following preparations: 10 mL media only
(negative control) for 48 hours, 10 mL of IC50 cisplatin for 48 hours, 10 mL of IC50 EF-24
in DMSO for 24 hours, 10 mL of IC50 cisplatin in media for 24 hours followed by aspiration
and addition of IC50 EF-24 in DMSO for 24 hours. After 48-hour incubation, media was
aspirated out of each dish and cells were washed with 2 mL of PBS in triplicate. Cells were
then detached by adding 1 mL Accutase (Thermo Fisher) to each dish. Cells were then
transferred to individual micro-centrifuge tubes and 0.5 mL of PBS was added to each tube.
Each tube was then spun for 5 minutes at 1000 rpm. The supernatant was discarded, and
the pellet re-suspended in each tube with 500 µL of 10 µM ROS indicator dye [2',7'dichlorodihydrofluorescein diacetate (H2DCFDA)] (Invitrogen, Carlsbad, CA) in PBS.
Each tube was incubated for 30 minutes at 37°C in 5% CO2. Next, tubes were centrifuged
for 5 minutes at 1000 rpm. The supernatant was removed, and the cells washed with 1 mL
of PBS in triplicate. Cells were re-suspended in 1 mL of PBS. The tubes were then
analyzed with a BD Accuri P6 (Franklin Lakes, NJ) flow cytometer. The sample analysis
limit was set to 20,000 events, and data obtained from the FL1 channel was used to
determine fluorescence values as a percent of control.

2.5. Statistical Analysis

8

For the ROS and caspase assays, a two-way ANOVA (Tukey’s multiple
comparisons test; p ≤ 0.05) was performed, except that for the 24-hour ROS assay, an
unpaired two tailed t-test was used. All statistical analyses were performed in PRISM
(GraphPad, version 6, La Jolla, CA). IC50 values for cisplatin and EF-24 were calculated
in PRISM using a sigmoidal, four parameter logistic equation, from PRISM derived values
using the equation, y = mx + b or using ED50plus v1.0 online software. MTT assay
standard deviation values were calculated using ED50plus.
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3. RESULTS
3.1 Cellular viability assay
The colorimetric MTT assay was used to measure if cisplatin, EF-24 and cisplatinEF-24 combination treatment reduced cell viability in the four cell lines. In the two cancer
cell lines, A2780 and A2780cis, EF-24 reduced cell viability more than cisplatin (Table 1).
While in A2780 the combination of cisplatin with EF-24 had approximately the same effect
as cisplatin, the combination treatment in A2780cis reduced cell viability below that of the
cisplatin only treatment. Due to its engineered resistance to cisplatin, all IC50 values were
increased in the A2780cis cell line compared to those observed in the A2780, cisplatinsensitized cell line (Table 1). In the two non-cancer cell lines, cisplatin treatment reduced
cellular viability more than EF-24 in the HEI-OC1 cell line, but the opposite effect was
observed in HEK-293T cell culture (Table 1). In the HEK-293T cell line, combining
cisplatin with the curcuminoid further decreased viability. These results suggest that the
effect of these treatments against cancer and non-cancer cell viability follows this order:
EF-24 < EF-24 + cisplatin < cisplatin.

3.2 Caspase assays
Analysis of apoptotic signaling through pathways incorporating caspases-3, -7, -8
and -9 was performed using a luminogenic assay that measures caspase activity. In the
A2780 cell line, only cisplatin treatment significantly increased caspase-8 activity to 122%
of that measured in the control (p < 0.05; Fig. 1A). However, when caspase-9 activity was
measured in A2780, all treatments caused increased activity. EF-24 treatment was
significantly different compared to control (113% of control; p < 0.05), while cisplatin
10

(140% of control) and the combination treatment (147% of control) exhibited a more robust
effect when compared to control (p < 0.0001; Fig. 1B). A similar trend was found with
respect to caspase-3/7 activity; EF-24 treatment showed an increased effect compared to
control (130% of control; p < 0.01). Both cisplatin (330% of control) and the combination
treatment (326% of control) exhibited increased caspase activity when compared to control
(p < 0.0001; Fig. 1C).
Similar results were obtained for the different caspases in the A2780cis cell line.
Specifically, there was a general increase in activity from lowest to highest in the order of
cisplatin, EF-24 and the combination treatment. For example, when caspase-8 activity was
measured, cisplatin treatment caused significantly increased activity (127% of control; p <
0.05), while EF-24 had higher activity (205% of control; p < 0.0001) and the combination
treatment exhibited the highest amount of activity when compared to control (250% of
control; p < 0.0001; Fig. 2A). The caspase-9 activity trend was similar to caspase-8, except
that cisplatin caused a non-significant increase in activity (139%; p > 0.05) and EF-24 and
the combination treatment caused significantly increased activity (237% and 308% of
control, respectively; both p < 0.0001; Fig. 2B). Caspase -3/7 activity was also elevated for
all treatment categories. Cisplatin-treated cells increased significantly compared to control
(168% of control; p < 0.01), while both EF-24 (288% of control) and the combination
treatment (402% of control) had even higher activity compared to control (both p < 0.0001;
Fig. 2C).
In HEK-293T cells, caspase-8 activity increased in cisplatin-treated cells only
(136% of control; p < 0.001) compared to control; whereas, EF-24 and the combination
treatment did not exhibit altered activity (Fig. 3A). Caspase-9 activity was reduced during
11

cisplatin-EF-24 treatment (81% of control; p < 0.05), while the other treatments were not
significantly different than control (p > 0.05; Fig. 3B). Treatment with cisplatin, EF-24,
and the combination of cisplatin + EF-24 did not cause a significant change in caspase -3/7
activity compared to control (p > 0.05; Fig. 3C).
When the caspase assays were performed in HEI-OC1 cells, a very similar trend
was exhibited by all of the caspases. Specifically, EF-24 reduced caspase activity (caspase8, 69%; caspase-9, 66%; caspases-3/7, 66% of control; all p < 0.0001; Fig. 4A-C).
However, cisplatin treatment increased caspase activity (caspase-8, 229%; caspase-9,
234%; caspases-3/7, 234% of control; all p < 0.0001; Fig. 4A-C). Similar to cisplatin
treatment, when cisplatin was combined with EF-24, activity increased for all of the
caspases (caspase-8, 195%; caspase-9, 200%; caspases-3/7, 200% of control; all p <
0.0001; Fig. 4A-C).

3.3 Reactive oxygen species assay
Cellular reactive oxygen species (ROS) levels were measured using a fluorescent
flow cytometry assay. In the A2780 cancer cell line, both cisplatin treatment (159% of
control; p < 0.01) and the cisplatin-EF-24 combination (199% of control; p < 0.001) caused
significantly increased ROS production compared to control; whereas, EF-24 treatment
reduced ROS yield (89% of control) but this was not statistically different from controls
(Fig. 5A).
Similarly, in the A2780cis cancer cell line both cisplatin (163% of control; p < 0.01)
and the combination treatment (140% of control; p < 0.05) caused increased ROS levels;
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whereas, unlike A2780, EF-24 treatment caused significantly decreased ROS levels
compared to control (67% of control; p < 0.05; Fig. 5B).
In the two non-cancer cell lines, our experiments with HEI-OC1 showed that
treatment with cisplatin and the cisplatin-EF-24 combination caused statistically reduced
ROS levels at a 48-hour time point (27% of control and 24% of control respectively; both
p < 0.0001) compared to control, while EF-24 was not significantly different than control
(p > 0.05; fig. 5C). To further evaluate the effect of cisplatin on this cell line, an additional
ROS assay was performed at a 24-hour time point. This singular experiment with cisplatin
showed that cisplatin treatment caused increased ROS production compared to control,
although not statistically significant (143% of control; p > 0.05; Fig. 6). In the HEK-293T
cell line, no statistically significant different change in ROS levels were observed between
any of the treatment categories (Fig. 5D).
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Table 1: IC50 values for cisplatin, EF-24, and their combination in cell cultures
Mean ± standard deviation IC50 values for cisplatin, EF-24, and their combination for each
cancer (A2780, A2780cis) and non-cancer (HEI-OC1, HEK-293T) cell line examined.
IC50 (μM)
Cell Line

Cell Type

Cisplatin

EF-24

Cisplatin + EF-24

A2780

Ovarian (cisplatin-sensitive)

2.50 ± 0.19

0.62 ± 0.25

2.84 ± 1.29

A2780cis

Ovarian (cisplatin-resistant)

6.63 ± 0.55

1.47 ± 0.74

3.50 ± 0.43

HEI-OC1

Mouse auditory hybridoma

5.64 ± 3.84

7.37 ± 3.84

0.99 ± 0.05

HEK-293T

Human endothelial kidney

4.07 ± 0.82

2.28 ± 2.13

1.73 ± 1.35
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Figure 1: A2780 caspase activity signals through caspases-9, -3 and -7
(A-C) Cis = cisplatin, EF = EF-24, Cis/EF = cisplatin + EF-24, Cont = control. (A)
Caspase-8 activity increases in cisplatin-treated cells (dark gray) only compared to control
(white). (B) Cisplatin and the combination cisplatin + EF-24 (checkered gray) treatment
increase caspase-9 activity greater than EF-24 (light gray) treatment compared to control.
(C) Similar to caspase-9, cisplatin and the combination of cisplatin + EF-24 treatments
increase caspase-3/7 activity more so than EF-24 alone compared to control. n = 6; * p <
0.05; *** p < 0.001; **** p < 0.0001.
15

Figure 2: Cisplatin + EF-24 causes increased caspase activity compared to EF-24 or
cisplatin alone in A2780cis cells
(A-C) Cis = cisplatin, EF = EF-24, Cis/EF = cisplatin + EF-24, Cont = control. (A)
Caspase-8 activity increases most in cisplatin + EF-24-treated cells (checkered gray),
followed by EF-24 (light gray), and cisplatin (dark gray) compared to control (white). (B)
Similarly, caspase-9 activity increases most in cisplatin + EF-24-treated cells, followed by
EF-24, and cisplatin compared to control. (C) Caspase-3/7 activity increases most in
cisplatin + EF-24-treated cells, followed by EF-24, and cisplatin compared to control. n =
6; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
16

Figure 3: Caspases-8 and -9 activity is altered during cisplatin, EF-24, and combination
treatments in HEK-293T cells
(A-C) Cis = cisplatin, EF = EF-24, Cis/EF = cisplatin + EF-24, Cont = control. (A)
Caspase-8 activity increases in cisplatin-treated cells (dark gray) compared to control
(white). (B) Caspase-9 activity significantly decreases in cisplatin + EF-24-treated cells
(checkered gray) compared to control. (C) Caspase-3/7 activity is not significantly altered
by cisplatin, EF-24 (light gray), or combination treatment compared to control. n = 6; * p
< 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
17

Figure 4: EF-24 treatment decreases caspase activity while cisplatin and combination
treatments increase caspase activity in HEI-OC1 cells
(A-C) Cis = cisplatin, EF = EF-24, Cis/EF = cisplatin + EF-24, Cont = control. (A)
Caspase-8 activity increases most in cisplatin-treated cells (dark gray), followed by
cisplatin + EF-24 (checkered gray), while EF-24 (light gray) causes a decrease compared
to control (white). (B) Similarly, caspase-9 activity increases most in cisplatin-treated cells,
followed by EF-24, and decreased with EF-24 compared to control. (C) Caspase-3/7
activity also increases in cisplatin and cisplatin + EF-24-treated cells, with EF-24 causing
a decrease compared to control. n = 6; **** p < 0.0001.
18

Figure 5: ROS production varies between cancer and non-cancer cell lines
(A-D) Cis = cisplatin, EF = EF-24, Cis/EF = cisplatin + EF-24, Cont = control, RFU =
relative fluorescence units. (A) Cisplatin + EF-24 treatment causes increased ROS in
A2780 cells, followed by cisplatin, while EF-24 does not significantly change ROS
production compared to control. (B) Cisplatin treatment causes increased ROS in A2780cis
cells, followed by cisplatin + EF-24, while EF-24 treatment caused significant decrease in
ROS production compared to control. (C) Cisplatin and cisplatin + EF-24 treatment both
caused significant decreases in ROS production, whereas EF-24 treatment had no statistical
significance compared to control for HEI-OC1 cells. (D) Cisplatin, EF-24, and the
combination of cisplatin + EF-24 did not significantly alter ROS production compared to
control for HEK-293T cells. n = 6; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
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Figure 6: Cisplatin ROS production in HEI-OC1 at a 24-hour time point
Cis = cisplatin, Cont = control, RFU = relative fluorescence units. Cisplatin treatment
caused a non-significant increase in ROS production in HEI-OC1 cells at a 24-hour time
point. n = 6; p > 0.05.
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4. DISCUSSION
One strategy in chemotherapy is to find drugs that signal in different pathways and
act on separate mechanisms to promote cancer cytotoxicity while preventing negative sideeffects in non-cancerous cells (Dasari et al. 2014; Dugbartey et al. 2016). For example, the
combination of cisplatin and curcumin can have increased anti-cancer effects, but curcumin
may be able to reduce cisplatin-induced ototoxicity and nephrotoxicity (Fetoni et al. 2014;
Salehi et al. 2014; Topcu-Tarladacalisir et al. 2016; Rezaee et al. 2017).
Both cisplatin and EF-24 can reduce cancer cell viability by acting through
caspases-3/7 and -8, and -9 and altering ROS production (Tan et al. 2010; Marullo et al.
2013; Karasawa et al. 2015; He et al. 2016; Skoupa et al. 2017). In this project, we analyzed
the effects of cisplatin, EF-24 and their combination on cancer and non-cancer cell
viability, caspase signaling and ROS production using the MTT assay, luminescence assays
and flow cytometry.
Chemotherapy agents that act on different pathways might cause decreased cellular
viability in cancer cells when combined while having reduced toxicity in non-cancer cells.
We used the MTT assay to measure the cytotoxic effects of cisplatin, EF-24 and their
combination in two cancer cell lines as well as two non-cancer cell lines derived from
auditory and renal tissues that are often damaged by cisplatin treatment. Our results show
that cisplatin treatment suppresses cellular viability in both the A2780 and A2780cis cell
lines which corroborated previous studies (McEvoy et al. 2015; Kielbik et al. 2018; Table
1). Specifically, cisplatin had a stronger effect against cisplatin-sensitive as opposed to
cisplatin-resistant cells, which would be expected if cisplatin resistance was properly
maintained in the A2780cis cell line. EF-24’s effect against cellular viability has been
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assessed in A2780 cells (Zhang et al. 2013), but not in A2780cis cells to date. Not unlike
cisplatin, EF-24 treatment had a slightly stronger effect against cellular viability in the
A2780 than in the A2780cis cell line (Table 1). This could mean that EF-24 signaling is
similar to cisplatin and that a cisplatin resistance mechanism may similarly attenuate the
effect of the curcuminoid as it does for the platinum compound. When we next examined
the effect of combinations of cisplatin and EF-24, we temporally separated the treatments
and applied the curcuminoid after cisplatin as EF-24 is solubilized in DMSO, which
chemically inactivates cisplatin (Fischer et al. 2008; Hall et al. 2014; Raghavan et al.
2015). However, we found that the combination treatment IC50 values were very similar
to those of cisplatin and EF-24. This result suggests that in these cancer cell lines, cisplatin
and EF-24 either do not signal through different pathways or that the temporal separation
of cisplatin and the curcuminoid may prevent potentiation of either compounds if they act
through separate pathways.
We then used the MTT assay to assess the effect of cisplatin, EF-24 and their
combination on HEI-OC1 and HEK-293T cell viability. Our results (Table 1) showed that
cisplatin treatment had a very strong effect against cell viability in both cell lines consistent
with prior studies (Kalinec et al. 2016; He et al. 2019). However, the effect of EF-24 on
the viability of these non-cancer cell lines had not yet been established. We found that the
curcuminoid caused reduced viability similar to cisplatin (Table 1). This result could mean
that cisplatin and EF-24 act in both cell lines through the same pathways. Our combination
treatment experiments showed that EF-24 is not able to counteract the effect of cisplatin in
either cell line. In fact, the IC50 values obtained when the compounds were combined in
both cell lines were lower than those for the individual treatments. This result suggests
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that cisplatin and EF-24 may act through the same pathways to produce a potentiated effect.
Interestingly, the effect of these compounds individually and together on cell viability is
very similar in both the cancer and non-cancer cell lines. Both HEI-OC1 and HEK-293T
have been engineered to re-enter the cell cycle and undergo proliferation (DuBridge et al.
1987; Kalinec et al. 2014; Kalinec et al. 2016). Therefore, it is possible that both cell lines
exhibit cancer-like cell signaling characteristics that would cause them to exhibit a similar
response to cisplatin, EF-24 or combination treatment, and unlike what might occur in the
original source tissue.
Cisplatin and EF-24 could signal through distinct caspase pathways to more
effectively target cancer and prevent the platinum compound’s side effects. Our caspase
assay data suggests that each cell line may demonstrate unique apoptosis signaling
characteristics and responses to the different treatments. For example, in the cisplatin
sensitive A2780 cell line, cisplatin treatment caused greater caspase-9 and caspase-3/7
activity (Fig. 1A-C), while caspase-8 activity did not increase as much as the other two
(Fig. 1A). EF-24 treatment, however, caused increases in caspase-9 and caspase-3/7
production only (Fig. 1B), indicating that this curcuminoid signals through the intrinsic
mitochondrial apoptosis pathway similar to curcumin (Zheng et al. 2006). Combining EF24 with cisplatin in the A2780 cell line did not cause increased caspase-8 activity compared
to cisplatin-only treated cells. These results indicate that EF-24 might counteract cisplatin
and that the two compounds may signal through different apoptotic pathways. Comparing
our results for caspases-9 and -3/7 shows that each treatment exhibits largely similar
activity for both caspases (Fig. 1B-C), suggesting that in A2780, apoptosis is induced by
cisplatin and EF-24 through a pathway involving caspase-9 signaling through caspase-3/7,
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comparable with previous reports of cisplatin’s effect on caspase activity in this cell line
(Henkels et al. 1999; Singh et al. 2013). One explanation for the lack of a synergistic effect
in the studied caspases could be the temporal separation between application of EF-24 and
cisplatin, as both compounds are not concomitantly applied. In other words, the effect of
EF-24 may occur after cisplatin’s effect has largely been attenuated. However, it has been
shown in other cell lines that EF-24 can induce apoptosis through caspases-9 and -3 (Yang
et al. 2014; He et al. 2016), which supports the interpretation that in A2780, caspase-9 and
-3/7 signaling are important contributors to cisplatin and EF-24 modulated cell death.
Caspase signaling in a cisplatin resistant cell line could be different than what
occurs in a cisplatin sensitive cell line. With the exception of cisplatin treatment for
caspase-9, which was not significantly different than control, we found a very similar
activity profile between the different caspases and the treatments in the A2780cis cell line.
Specifically, caspase activity followed a profile where the combination treatment caused
the greatest increase in activity followed by EF-24 and cisplatin treatment caused the least
increase in caspase activity (Fig. 2A-C). These results suggest that cisplatin and EF-24
signal in the same caspase pathways under conditions of cisplatin resistance and that EF24 can potentiate the effect of cisplatin in the A2780cis cell line.
The effects of cisplatin and EF-24 treatment on caspase-associated signal
transduction in non-cancer cells could be different than those in our cancer cell lines. In
HEK-293T, cisplatin treatment caused an increase in caspase-8 activity only, while EF-24
treatment did not cause any significant change in caspase activity and the combination of
EF-24 and cisplatin reduced activity through caspase-9 only (Fig 3A-C). These results
suggest that HEK-293T cells undergo cell death via other mechanisms that do not
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incorporate these caspases. One possible interpretation is that caspase signaling could be
occurring through the endoplasmic reticulum mediated caspase-12 or through another
intrinsic mechanism, such as apoptosis inducing factor (AIF; Karasawa et al. 2015). It is
also possible that the temporal separation of the application of these compounds is
preventing accurate identification of caspase activation in this cell line. Future research is
needed to clarify the apoptotic pathway signaling of these compounds in renal cells.
Unlike what was observed in the HEK-293T cell line, our HEI-OC1 data suggests
that cisplatin and EF-24 can have opposing effects on caspase signaling. We observed an
identical pattern of activity for all treatments where cisplatin increased the activity of these
caspases, but EF-24 counteracted caspase activity (Fig. 4A-C). Also, the combination
treatment caused caspase activity to decrease relative to cisplatin activity for both caspase
-8 and -9 (Fig. 4A-B). Interestingly, as EF-24 caused decreased caspase activity, this could
indicate an application as an otoprotectant with anticancer activity. Our results suggest that
EF-24 may signal differently than cisplatin in cells derived from auditory tissue and could
potentially counteract cisplatin’s modulation of these caspases in this cell line.
Our reactive oxygen species data suggests that each cell line may exhibit unique
signaling characteristics and responses to cisplatin and EF-24 treatment. In the A2780 cell
line, which is cisplatin sensitive, cisplatin treatment caused a significant increase in ROS
yield (Figure 5A). However, EF-24 treatment did not alter reactive oxygen species levels
suggesting that it did not function as an ROS scavenger similar to what is observed in
curcumin-treated cancer cells (Hussain et al. 2017). Also, the absence of EF-24 inducing
a change in ROS levels suggests that unlike cisplatin, the curcuminoid does not modulate
a pathway or cellular target, e.g., the mitochondria, that is associated with ROS production.
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Interestingly, when we combined cisplatin with EF-24 in A2780, there was a significant
increase in ROS compared to cisplatin only treated cells. This result suggests that EF-24
may signal through a different pathway than cisplatin that, under conditions of cisplatin
co-treatment, can potentiate cisplatin’s function to generate reactive oxygen species and
increase ROS levels beyond those produced by cisplatin alone. It is uncertain from our
data if this effect constitutes a form of enhanced cisplatin sensitization as has been reported
in some cancer cell lines (Galluzi et al. 2014; Engelke, et al. 2016; El-Senduny et al., 2016).
Our results obtained with the cisplatin-resistant A2780cis cell line may provide
additional insights into how EF-24 and cisplatin act in reactive oxygen species signaling.
When treated with cisplatin, ROS yield was comparable with that observed in the cisplatinsensitive A2780 cell line (Figure 4B). However, EF-24 treatment caused a significant
reduction as did the combination of cisplatin with the curcuminoid. These results suggest
that under conditions of cisplatin-resistance, EF-24 may counteract a different set of
pathways than those modulated in cisplatin-sensitized A2780 cells. It is possible that EF24 could act, like curcumin, as a ROS scavenger in some physiological circumstances and
cause a reduction in ROS as has been reported in some cancer cell lines (Tan et al. 2010).
However, in other cancer cell lines, EF-24 can form adducts with the antioxidant
glutathione and there is an associated but non-toxic increase in ROS production (Skoupa
et al., 2017). It is possible that EF-24 and cisplatin might target discrete ROS pathways in
both cancer cell lines but that the changes in ROS production is not significant in inducing
apoptosis.

Further, even if EF-24 counteracts a specific antioxidant, compensatory

mechanisms may be activated that can offset this effect. Compensation could also occur
at various steps in apoptotic pathways integrating reactive oxygen species, and, therefore,
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there could be distinct temporal ROS effects in cisplatin-sensitive as opposed to resistant
cells. Also, our ROS assay uses a H2DCFDA dye, which primarily detects H2O2 (Oparka
et al. 2016). Thus, it might be possible that the ROS assay is not able to adequately assess
the contribution of other ROS in cancer cell apoptosis signal transduction.
The non-cancer cell line ROS data suggests that cisplatin and EF-24 may act
through different signaling mechanisms with distinct temporal characteristics from those
of the cancer cell lines. As prior studies have shown that cisplatin is an ototoxin that acts
against auditory hair cells by increasing reactive oxygen species (Cepeda et al. 2007;
Karasawa et al. 2015; Kim et al. 2016), we were surprised to find that cisplatin treatment
significantly decreased ROS in HEI-OC1 cells (Figure 5C). Interestingly, the EF-24
treatment did not change reactive oxygen species levels; however, the combination of EF24 with cisplatin also had significantly reduced ROS yield similar to the cisplatin only
treatment. This result suggests that at the 48-hour time point when these experiments were
performed that any effect against ROS production was primarily from the presence of
cisplatin. As the reduced reactive oxygen species yield at 48 hours could be a late stage
effect and not represent what occurs at earlier time points, we treated HEI-OC1 cells with
cisplatin for 24 hours and then measured ROS again (Figure 6). At this earlier time point,
ROS yield was elevated, but was not significantly higher than the control. Nonetheless,
the 24-hour result suggests that cisplatin treatment might increase reactive oxygen species
production at an earlier stage, which could then activate apoptotic mechanisms. It is also
possible that the decline in ROS exhibited later, at 48 hours, is due to anti-ROS
compensation from increased expression of anti-oxidant proteins which have been
identified in cancer cells (Liou et al. 2010). Further, some drugs can cause alterations in
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ROS reduction in cancer cells and modulate anti- and proantioxidant proteins (Badia et al.
2016). As the HEI-OC1 cell line is an auditory hybridoma with cancer like proliferative
properties that can exhibit altered ROS production after drug exposure (Kalinec et al. 2014;
Kalinec et al. 2016), it is also possible that their oxidative responses to cisplatin and EF24 could be different than those of unaltered, nonproliferative auditory hair cells.
Unlike the other cell lines, the HEK-293T cells did not exhibit any change in ROS
production for any treatment category (Figure 5D). HEK-293T cells are modified renal
cells that undergo temperature sensitive driven cancer cell like proliferation (DuBridge et
al. 1987). These cells have been used as a model for cisplatin-mediated nephrotoxicity and
combinations of cisplatin or other drugs with anti-oxidants can counteract ROS generation
in this cell line (Xu et al. 2018; He et al. 2019). As these studies evaluated an earlier time
point, and used antioxidant pretreatment before cisplatin administration, it could be that
cisplatin causes an early phase ROS elevation in HEK-293T cells that cannot be
counteracted by subsequent EF-24 treatment. This interpretation suggests that reactive
oxygen species signaling in HEK-293T cells might exhibit temporal characteristics which
could differ in a particular pathway and prevent cisplatin or EF-24 from affecting ROS
either individually or together if the timing of their application is not appropriate.
This project investigated how combining cisplatin and EF-24 treatment affects
cellular viability, apoptotic mechanisms and ROS production in two cancer cell lines
(A2780 and A2780cis) and two noncancer cell lines (HEK-293T and HEI-OC1). Our
results suggest that the effect of all three drug treatment categories against cell viability
was reduced in A2780cis compared to A2780. Also, all treatment categories had strong
effects against cell viability in the noncancer cell lines, but the strongest effect was caused
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by the combination treatment. Overall, the results suggest that all treatments similarly
affected the different cell types, but the general trend for drug efficacy was EF-24 > EF-24
+ cisplatin > cisplatin. The apoptotic signal transduction pathway analysis suggests that in
A2780 cells, caspase-3/7 activity may be from caspase-9 and not caspase-8 in A2780. In
A2780cis cells, EF-24 may be counteracting cisplatin resistance. In HEK-293T cells,
apoptosis may signal through other pathways than those integrating caspases-3/7, -8,-9. In
HEI-OC1 cells, EF-24 reduced caspase-3/7, -8 and -9 activity, while cisplatin and the
combination treatment increased activity for these caspases. For the flow cytometry ROS
assays, in A2780 cells, EF-24 might increase cisplatin’s induction of ROS, while the
opposite was observed in the A2780cis cell line. HEK-293T cells did not exhibit altered
ROS production at the 48-hour interval tested; whereas, cisplatin treatment caused reduced
ROS yield at 48 hours in HEI-OC1 cells but not at 24 hours post-treatment. Our results
with the non-cancer cells suggest that the time interval of treatment may be important in
evaluating ROS production from these compounds. Future directions could include a
western blot analysis investigating alternative apoptosis signaling pathways incorporating
caspase-12 or apoptosis inducing factor (AIF). Also, RNA interference could be utilized to
reduce caspase expression to further clarify the relationship between these proteins. ROS
experiments could also be performed at earlier time points to determine if there are distinct
temporal effects from the treatments.

Obtaining this information could assist the

development of novel chemotherapy treatments with improved patient prognoses.
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